Developer docs
API playgroundTry for free, no card

Search company profiles

MaxCyte

Full company profile

uuid0000roz

Namestring
MaxCyte
Legal namestring
MaxCyte, Inc.
Websiteurl
maxcyte.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

MaxCyte, Inc. (NASDAQ: MXCT) is a publicly traded life sciences tools company founded in 1999 and headquartered in Rockville, Maryland. The company develops and commercializes Flow Electroporation technology, a non-viral cell engineering method that uses controlled electrical pulses to transiently permeabilize cell membranes and deliver nucleic acids, proteins, and other molecules into eukaryotic cells. Its ExPERT platform spans five instruments covering the full development continuum: the DTx (96-well discovery), ATx (small-to-mid scale research), STx (protein and vaccine production), GTx (cGMP clinical manufacturing), and VLx (200-billion-cell gram-scale production). The instruments share common consumables and protocols, enabling seamless scale-up without process reoptimization, and are sold alongside proprietary processing assemblies and buffers.

MaxCyte monetizes through three streams: (1) hardware and consumable sales of ExPERT instruments and proprietary disposables to academic, biotech, and pharmaceutical customers; (2) the Strategic Platform Licensing (SPL) program, a milestone-based licensing model under which cell and gene therapy developers gain access to the electroporation platform, with 32+ active SPL partners including CRISPR Therapeutics and Vertex Pharmaceuticals (whose CASGEVY became the first FDA-approved non-viral CRISPR-based therapy using MaxCyte's technology); and (3) SeQure Dx services for gene editing off-target and on-target risk assessment, following the January 2025 acquisition of SeQure Dx. The platform is supported by an FDA Master File continuously maintained since 2002, ISO 9001 manufacturing, and 21 CFR Part 11-compliant instruments.

The company serves cell and gene therapy developers (its primary segment), protein and biologics producers, drug discovery and screening groups, and vaccine/mRNA therapeutics developers. Distribution combines direct enterprise sales in the US with a network of regional distributors across Asia-Pacific, Europe, and Israel. FY2025 revenue was $33.0M (down 15% YoY), with $155.6M in cash and a $16M+ reduction in annual cash burn; 2026 guidance is $30-32M as core instrument revenue continues to face headwinds offset by 62% growth in SPL program revenue.

Short descriptiontext

MaxCyte (NASDAQ: MXCT) develops Flow Electroporation-based non-viral cell engineering instruments and consumables, serving cell and gene therapy developers, biologics producers, and academic researchers worldwide through direct sales, a Strategic Platform Licensing model, and the SeQure Dx gene editing risk assessment services acquired in 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electroporation instruments, cell engineering technology, flow electroporation, gene editing services, cell therapy manufacturing
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Engineering Instrumentation and Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Electroporation Instruments and Consumables
TypeHardware Sales
Description

Sale of electroporation instruments (ExPERT DTx, ATx, STx, GTx, VLx) and associated consumables (Processing Assemblies, Reagents, Buffers) for cell engineering applications. Instruments range from research-use-only to GMP-compliant manufacturing systems.

stocktitan.net
2Strategic Platform Licensing (SPL)
TypeLicensing Royalties
Description

Partnership-driven licensing model providing access to MaxCyte's electroporation technology. The licensing model is structured to take effect after partners reach clinical and commercialization milestones, creating a win-win approach. Revenue from SPL programs grew 62% to $3.4M in Q1 2026.

maxcyte.com
3SeQure Gene Editing Services
TypeProfessional Services
Description

Gene editing risk assessment services including screening, nomination, and confirmation assays for off-target and on-target editing characterization. Supports IND submissions and regulatory compliance for cell and gene therapy developers.

maxcyte.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Infrastructure, Supply Chain, Marketing or Sales
Pricing details3 tiers
1Electroporation instruments (DTx, ATx, STx, GTx, VLx) with varying scale capabilities
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Instruments available for research-use-only (DTx, ATx, STx) and GMP-compliant manufacturing (GTx, VLx). Pricing not publicly disclosed; quote-based sales.

maxcyte.com
2Processing assemblies and reagents
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Consumable products including Processing Assemblies (OC-25x3, R-50x3, R-50x8, OC-100, OC-100x2, OC-400, R-1000, CL-1.1, R-20K, CL-2, VLXD, R-1L, R-50x96), Buffers (EBP-1, EBP-5, Closed Process Buffer GMP versions), and Accessories. Available in RUO and GMP grades.

maxcyte.com
3SeQure gene editing risk assessment services
ModelOtherBilling cadenceMulti-year contract
Notes

Service-based pricing for gene editing assays (Guide Profiler, Guide Select, ONE-seq, DEUX-seq, GUIDE-seq, Amplicon-seq, SAFER Detection). Pricing not publicly disclosed; consultation-based engagement.

maxcyte.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ExPERT
Description

Electroporation technology platform for cell engineering across research and manufacturing scales

maxcyte.com
+3 more records
Core offering1 text field

MaxCyte develops and commercializes non-viral Flow Electroporation technology for cell engineering, offering a portfolio of five ExPERT instruments (DTx, ATx, STx, GTx, VLx) that scale from discovery through GMP manufacturing. The company sells proprietary processing assemblies, buffers, and reagents as consumables, and provides gene editing risk assessment services through its SeQure sub-brand. Customers include biotech firms, biopharmaceutical companies, and academic institutions developing cell therapies, gene therapies, vaccines, and biologics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems in CAR-T manufacturing (VectorBuilder partnership data)
+3 more records
Product overview1 text field

MaxCyte offers the ExPERT platform, a family of electroporation instruments designed for non-viral cell engineering across the full development continuum from discovery through commercial manufacturing. The platform comprises five distinct instruments: DTx (96-well high-throughput for discovery), ATx (small-to-medium scale R&D), STx (protein/vaccine production), GTx (cGMP clinical manufacturing), and VLx (gram-scale protein production). These instruments share common consumables and protocols, enabling seamless scale-up without reoptimization. The SeQure sub-brand provides comprehensive gene editing risk assessment services across three tiers—screening (Guide Profiler, Guide Select), nomination (ONE-seq, DEUX-seq, GUIDE-seq), and confirmation (Amplicon-seq, SAFER Detection)—addressing FDA guidance requirements for off-target and structural rearrangement assessment in cell and gene therapy development.

Product and service14 records
1ExPERT DTx
CategoryElectroporation Instrument
Description

High-throughput 96-well electroporation platform for research and drug discovery applications, processing up to 96 samples in a single three-minute run using detachable 8-well strip assemblies. Enables customizable protocols for diverse cell and cargo combinations with high cell viability and direct scalability to cGMP-compliant manufacturing across the ExPERT platform. Targeted at discovery and screening researchers.

2ExPERT ATx
CategoryElectroporation Instrument
Description

Small to medium scale electroporation instrument for research transfection, supporting 75,000 to 700 million cells with high efficiency and viability. Designed for research laboratories conducting cell therapy R&D and gene editing studies with reliable, reproducible protocols.

3ExPERT STx
CategoryElectroporation Instrument
Description

Scalable transfection system for complex proteins, vaccines, and biologics production. Supports 100,000 to 20 billion cells with efficient, reproducible transient transfection that can delay the need for stable cell line development. Used by researchers and process developers for antibody and vaccine production.

4ExPERT GTx
CategoryElectroporation Instrument
Description

Clinically validated, cGMP-compliant Flow Electroporation system for manufacturing of cell-based therapies, capable of transfecting up to 20 billion cells. Marketed as the only clinically validated electroporator developed specifically for cell therapy manufacturing, used in clinical and commercial cell and gene therapy production.

5ExPERT VLx
CategoryElectroporation Instrument
Description

High-capacity electroporation system for gram-scale protein production, capable of transfecting 200 billion cells in less than 30 minutes. Enables seamless transition from discovery to manufacturing with high throughput for antibody, biologics, and vaccine production.

6Processing Assemblies
CategoryConsumables
Description

Range of consumable devices providing options for project scale and throughput from discovery through cGMP manufacturing. Includes multiple volume formats (96-well strips, static assemblies, flow electroporation assemblies for closed-system processing) used with ExPERT instruments.

7Electroporation Buffer
CategoryConsumables
Description

Proprietary electroporation buffer available in multiple formats including GMP and closed-bag configurations. Animal-derived component free, 0.1 µm filtered, meeting technical, sterility, and endotoxin specifications. Compatible with all MaxCyte ExPERT instrument platforms.

8SeQure Guide Profiler
CategoryGene Editing Risk Assessment Service
Description

In silico screening assay enabling rapid evaluation of potential off-target effects associated with gene editing tools. Allows researchers to screen sgRNAs to understand on-target efficacy and off-target editing risks during early discovery and target validation.

9SeQure Guide Select
CategoryGene Editing Risk Assessment Service
Description

Biochemical screening assay for screening multiple guide RNAs in parallel. Variant-aware searching within a limited search space enables high-powered, low-cost risk assessment for guide RNA selection and program prioritization in gene editing programs.

10SeQure ONE-seq
CategoryGene Editing Risk Assessment Service
Description

Gold standard nomination assay for population-scale, variant-aware off-target detection. Combines candidate off-target enumeration, enrichment, and in vitro cutting with deep sequencing for high-sensitivity detection of low-frequency off-target events in gene editing programs.

11SeQure DEUX-seq
CategoryGene Editing Risk Assessment Service
Description

Biochemical, orthogonal nomination assay that validates and reinforces ONE-seq findings. Leverages in vitro cutting of genomic DNA followed by deep sequencing to determine potential off-target effects of gene editing tools.

12SeQure GUIDE-seq
CategoryGene Editing Risk Assessment Service
Description

Cell-based, orthogonal nomination assay that utilizes co-transfection of a DNA tag alongside gene editing tools to profile potential off-target effects in chosen cell types. Used by cell and gene therapy developers for IND-enabling risk assessment.

13SeQure Amplicon-seq
CategoryGene Editing Risk Assessment Service
Description

Confirmation assay providing high-sensitivity confirmation of on- and off-target edits in gene-edited cell lines and tissues. Targeted amplicon sequencing guided by nomination assay results, supporting IND submissions for cell and gene therapies.

14SeQure SAFER Detection
CategoryGene Editing Risk Assessment Service
Description

Confirmation assay confirming on-target, off-target, and homology-mediated structural rearrangements from gene editing. Addresses FDA expectations for structural rearrangement data to mitigate IND filing delays in cell and gene therapy programs.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Strategic partnership to co-develop next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-04
Description

Strategic Platform Licensing agreement for development of gamma delta T cell therapy programs. MaxCyte's Flow Electroporation technology will support gene editing in allogeneic T cell therapy manufacturing.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-07-31
Description

Strategic Platform Licensing agreement to advance TCR-T cell therapy pipeline. MaxCyte's Flow Electroporation technology will support non-viral gene editing in manufacture of Anocca's TCR-T cell therapies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-11
Description

Collaboration to improve manufacturing efficiencies and broaden adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT Electroporation platform with Ori's IRO manufacturing system aims to improve gene-edited T cell yield, shorten manufacturing timelines, and support seamless path from R&D to GMP production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MaxCyte partners with leading academic institutions, translational centers, and biopharmaceutical companies worldwide for cell and gene therapy development. The partnership-driven licensing model provides scalable solutions from discovery to commercialization, with expert support and proven scalability. Company has collaborated in 35 clinical trials with partners in pharma and biotech developing treatments for cancer, CNS disorders, and rare genetic diseases.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Thermo Fisher offers the Neon NxT electroporation system and BTX electroporation/cell fusion instruments, directly competing with MaxCyte's ExPERT platform for cell engineering market share among cell therapy developers and academic researchers.

TypeDirect peer
Description

Bio-Rad's Gene Pulser and electroporation product lines compete directly with MaxCyte's Flow Electroporation technology across research and cell therapy manufacturing applications, serving similar biopharma and academic customers.

TypeDirect peer
Description

Harvard Bioscience's BTX division offers electroporation and electrofusion instruments for cell engineering, competing directly with MaxCyte in transfection equipment for research and clinical cell therapy manufacturing.

TypeEmerging player
Description

Miltenyi Biotec offers a broad portfolio of cell therapy tools and instruments (including the CliniMACS platform), competing with MaxCyte for share among CAR-T and gene-edited cell therapy developers through complementary rather than identical cell engineering modalities.

TypeBroad incumbent
Description

Lonza is a leading cell and gene therapy CDMO offering process development and GMP manufacturing services that compete with portions of MaxCyte's SPL offering, while also serving many of the same cell therapy developers as customers.

TypeBroad incumbent
Description

Catalent is a major cell therapy CDMO providing process development and GMP manufacturing services, overlapping with MaxCyte's enabling-tools positioning as a partner to cell therapy developers seeking manufacturing solutions.

TypeBroad incumbent
Description

Sartorius provides bioprocessing equipment and cell therapy manufacturing solutions that compete in adjacent steps of the cell therapy workflow, serving many of the same biopharma customers with broader portfolios that include cell engineering alternatives.

TypeBroad incumbent
Description

Cytiva offers a broad portfolio of bioprocessing and cell therapy manufacturing equipment under Danaher, competing with MaxCyte at the manufacturing scale-up stage and serving overlapping cell therapy developer customers globally.

TypeDirect peer
Description

BEX is a Japanese manufacturer of electroporation equipment (including the CUY21 series) used for in vivo and ex vivo transfection, representing a regional direct competitor to MaxCyte in gene delivery instrumentation.

TypeOthers
Description

Agilent provides life sciences instrumentation and analytical tools serving similar biopharma and academic research customers as MaxCyte, and recently hired MaxCyte's incoming CFO from its investor relations function, signaling overlap in talent markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MaxCyte

Cell Engineering Instrumentation and Servicesmaxcyte.com

MaxCyte (NASDAQ: MXCT) develops Flow Electroporation-based non-viral cell engineering instruments and consumables, serving cell and gene therapy developers, biologics producers, and academic researchers worldwide through direct sales, a Strategic Platform Licensing model, and the SeQure Dx gene editing risk assessment services acquired in 2025.

What MaxCyte does

MaxCyte, Inc. (NASDAQ: MXCT) is a publicly traded life sciences tools company founded in 1999 and headquartered in Rockville, Maryland. The company develops and commercializes Flow Electroporation technology, a non-viral cell engineering method that uses controlled electrical pulses to transiently permeabilize cell membranes and deliver nucleic acids, proteins, and other molecules into eukaryotic cells. Its ExPERT platform spans five instruments covering the full development continuum: the DTx (96-well discovery), ATx (small-to-mid scale research), STx (protein and vaccine production), GTx (cGMP clinical manufacturing), and VLx (200-billion-cell gram-scale production). The instruments share common consumables and protocols, enabling seamless scale-up without process reoptimization, and are sold alongside proprietary processing assemblies and buffers.

MaxCyte monetizes through three streams: (1) hardware and consumable sales of ExPERT instruments and proprietary disposables to academic, biotech, and pharmaceutical customers; (2) the Strategic Platform Licensing (SPL) program, a milestone-based licensing model under which cell and gene therapy developers gain access to the electroporation platform, with 32+ active SPL partners including CRISPR Therapeutics and Vertex Pharmaceuticals (whose CASGEVY became the first FDA-approved non-viral CRISPR-based therapy using MaxCyte's technology); and (3) SeQure Dx services for gene editing off-target and on-target risk assessment, following the January 2025 acquisition of SeQure Dx. The platform is supported by an FDA Master File continuously maintained since 2002, ISO 9001 manufacturing, and 21 CFR Part 11-compliant instruments.

The company serves cell and gene therapy developers (its primary segment), protein and biologics producers, drug discovery and screening groups, and vaccine/mRNA therapeutics developers. Distribution combines direct enterprise sales in the US with a network of regional distributors across Asia-Pacific, Europe, and Israel. FY2025 revenue was $33.0M (down 15% YoY), with $155.6M in cash and a $16M+ reduction in annual cash burn; 2026 guidance is $30-32M as core instrument revenue continues to face headwinds offset by 62% growth in SPL program revenue.

MaxCyte firmographics

Firmographics
Name
MaxCyte
Legal name
MaxCyte, Inc.
Website
https://maxcyte.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
MaxCyte (NASDAQ: MXCT) develops Flow Electroporation-based non-viral cell engineering instruments and consumables, serving cell and gene therapy developers, biologics producers, and academic researchers worldwide through direct sales, a Strategic Platform Licensing model, and the SeQure Dx gene editing risk assessment services acquired in 2025.
Ownership category
akta.pro rank

MaxCyte industry classification

Industry
Product category
Cell Engineering Instrumentation and Services
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Electroporation instruments
  • Cell engineering technology
  • Flow electroporation
  • Gene editing services
  • Cell therapy manufacturing

Where MaxCyte is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MaxCyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Electroporation Instruments and Consumables: Sale of electroporation instruments (ExPERT DTx, ATx, STx, GTx, VLx) and associated consumables (Processing Assemblies, Reagents, Buffers) for cell engineering applications. Instruments range from research-use-only to GMP-compliant manufacturing systems.
  2. Strategic Platform Licensing (SPL): Partnership-driven licensing model providing access to MaxCyte's electroporation technology. The licensing model is structured to take effect after partners reach clinical and commercialization milestones, creating a win-win approach. Revenue from SPL programs grew 62% to $3.4M in Q1 2026.
  3. SeQure Gene Editing Services: Gene editing risk assessment services including screening, nomination, and confirmation assays for off-target and on-target editing characterization. Supports IND submissions and regulatory compliance for cell and gene therapy developers.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseElectroporation instruments (DTx, ATx, STx, GTx, VLx) with varying scale capabilities
Unit PricingPay-as-you-goProcessing assemblies and reagents
OtherMulti-year contractSeQure gene editing risk assessment services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

MaxCyte product offering

Product offering

Core offering

MaxCyte develops and commercializes non-viral Flow Electroporation technology for cell engineering, offering a portfolio of five ExPERT instruments (DTx, ATx, STx, GTx, VLx) that scale from discovery through GMP manufacturing. The company sells proprietary processing assemblies, buffers, and reagents as consumables, and provides gene editing risk assessment services through its SeQure sub-brand. Customers include biotech firms, biopharmaceutical companies, and academic institutions developing cell therapies, gene therapies, vaccines, and biologics.

Product overview

MaxCyte offers the ExPERT platform, a family of electroporation instruments designed for non-viral cell engineering across the full development continuum from discovery through commercial manufacturing. The platform comprises five distinct instruments: DTx (96-well high-throughput for discovery), ATx (small-to-medium scale R&D), STx (protein/vaccine production), GTx (cGMP clinical manufacturing), and VLx (gram-scale protein production). These instruments share common consumables and protocols, enabling seamless scale-up without reoptimization. The SeQure sub-brand provides comprehensive gene editing risk assessment services across three tiers—screening (Guide Profiler, Guide Select), nomination (ONE-seq, DEUX-seq, GUIDE-seq), and confirmation (Amplicon-seq, SAFER Detection)—addressing FDA guidance requirements for off-target and structural rearrangement assessment in cell and gene therapy development.

Differentiator

Problem solved

Functional benefit

Brands

  • ExPERT: Electroporation technology platform for cell engineering across research and manufacturing scales
  • SeQure
  • ExPERT DTx
  • Flow Electroporation

Products and services

  • ExPERT DTx High-throughput 96-well electroporation platform for research and drug discovery applications, processing up to 96 samples in a single three-minute run using detachable 8-well strip assemblies. Enables customizable protocols for diverse cell and cargo combinations with high cell viability and direct scalability to cGMP-compliant manufacturing across the ExPERT platform. Targeted at discovery and screening researchers.
  • ExPERT ATx Small to medium scale electroporation instrument for research transfection, supporting 75,000 to 700 million cells with high efficiency and viability. Designed for research laboratories conducting cell therapy R&D and gene editing studies with reliable, reproducible protocols.
  • ExPERT STx Scalable transfection system for complex proteins, vaccines, and biologics production. Supports 100,000 to 20 billion cells with efficient, reproducible transient transfection that can delay the need for stable cell line development. Used by researchers and process developers for antibody and vaccine production.
  • ExPERT GTx Clinically validated, cGMP-compliant Flow Electroporation system for manufacturing of cell-based therapies, capable of transfecting up to 20 billion cells. Marketed as the only clinically validated electroporator developed specifically for cell therapy manufacturing, used in clinical and commercial cell and gene therapy production.
  • ExPERT VLx High-capacity electroporation system for gram-scale protein production, capable of transfecting 200 billion cells in less than 30 minutes. Enables seamless transition from discovery to manufacturing with high throughput for antibody, biologics, and vaccine production.
  • Processing Assemblies Range of consumable devices providing options for project scale and throughput from discovery through cGMP manufacturing. Includes multiple volume formats (96-well strips, static assemblies, flow electroporation assemblies for closed-system processing) used with ExPERT instruments.
  • Electroporation Buffer Proprietary electroporation buffer available in multiple formats including GMP and closed-bag configurations. Animal-derived component free, 0.1 µm filtered, meeting technical, sterility, and endotoxin specifications. Compatible with all MaxCyte ExPERT instrument platforms.
  • SeQure Guide Profiler In silico screening assay enabling rapid evaluation of potential off-target effects associated with gene editing tools. Allows researchers to screen sgRNAs to understand on-target efficacy and off-target editing risks during early discovery and target validation.
  • SeQure Guide Select Biochemical screening assay for screening multiple guide RNAs in parallel. Variant-aware searching within a limited search space enables high-powered, low-cost risk assessment for guide RNA selection and program prioritization in gene editing programs.
  • SeQure ONE-seq Gold standard nomination assay for population-scale, variant-aware off-target detection. Combines candidate off-target enumeration, enrichment, and in vitro cutting with deep sequencing for high-sensitivity detection of low-frequency off-target events in gene editing programs.
  • SeQure DEUX-seq Biochemical, orthogonal nomination assay that validates and reinforces ONE-seq findings. Leverages in vitro cutting of genomic DNA followed by deep sequencing to determine potential off-target effects of gene editing tools.
  • SeQure GUIDE-seq Cell-based, orthogonal nomination assay that utilizes co-transfection of a DNA tag alongside gene editing tools to profile potential off-target effects in chosen cell types. Used by cell and gene therapy developers for IND-enabling risk assessment.
  • SeQure Amplicon-seq Confirmation assay providing high-sensitivity confirmation of on- and off-target edits in gene-edited cell lines and tissues. Targeted amplicon sequencing guided by nomination assay results, supporting IND submissions for cell and gene therapies.
  • SeQure SAFER Detection Confirmation assay confirming on-target, off-target, and homology-mediated structural rearrangements from gene editing. Addresses FDA expectations for structural rearrangement data to mitigate IND filing delays in cell and gene therapy programs.

Quantifiable outcome

  • 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems in CAR-T manufacturing (VectorBuilder partnership data)
  • +3 more outcomes

Companies that use MaxCyte

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

MaxCyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MaxCyte partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • VectorBuildercoreStrategic or Co-development Partner · 23 June 2026Strategic partnership to co-develop next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies.
  • Adicet BiocoreOEM/ Whitelabel/ Licensing Partner · 4 August 2025Strategic Platform Licensing agreement for development of gamma delta T cell therapy programs. MaxCyte's Flow Electroporation technology will support gene editing in allogeneic T cell therapy manufacturing.
  • Anocca ABcoreOEM/ Whitelabel/ Licensing Partner · 31 July 2025Strategic Platform Licensing agreement to advance TCR-T cell therapy pipeline. MaxCyte's Flow Electroporation technology will support non-viral gene editing in manufacture of Anocca's TCR-T cell therapies.
  • Ori BiotechcoreTechnology or Integration · 11 June 2025Collaboration to improve manufacturing efficiencies and broaden adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT Electroporation platform with Ori's IRO manufacturing system aims to improve gene-edited T cell yield, shorten manufacturing timelines, and support seamless path from R&D to GMP production.
  • Cell and Gene Therapy Developers (Academic and Industry Partners)coreStrategic or Co-development PartnerMaxCyte partners with leading academic institutions, translational centers, and biopharmaceutical companies worldwide for cell and gene therapy development. The partnership-driven licensing model provides scalable solutions from discovery to commercialization, with expert support and proven scalability. Company has collaborated in 35 clinical trials with partners in pharma and biotech developing treatments for cancer, CNS disorders, and rare genetic diseases.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

MaxCyte competitors and assessment

Company assessment

Direct peers

  • Thermo Fisher Scientific: Thermo Fisher offers the Neon NxT electroporation system and BTX electroporation/cell fusion instruments, directly competing with MaxCyte's ExPERT platform for cell engineering market share among cell therapy developers and academic researchers.
  • Bio-Rad Laboratories: Bio-Rad's Gene Pulser and electroporation product lines compete directly with MaxCyte's Flow Electroporation technology across research and cell therapy manufacturing applications, serving similar biopharma and academic customers.
  • Harvard Bioscience (BTX): Harvard Bioscience's BTX division offers electroporation and electrofusion instruments for cell engineering, competing directly with MaxCyte in transfection equipment for research and clinical cell therapy manufacturing.
  • BEX Co., Ltd. BEX is a Japanese manufacturer of electroporation equipment (including the CUY21 series) used for in vivo and ex vivo transfection, representing a regional direct competitor to MaxCyte in gene delivery instrumentation.

Emerging players

  • Miltenyi Biotec: Miltenyi Biotec offers a broad portfolio of cell therapy tools and instruments (including the CliniMACS platform), competing with MaxCyte for share among CAR-T and gene-edited cell therapy developers through complementary rather than identical cell engineering modalities.

Broad incumbents

  • Lonza Group: Lonza is a leading cell and gene therapy CDMO offering process development and GMP manufacturing services that compete with portions of MaxCyte's SPL offering, while also serving many of the same cell therapy developers as customers.
  • Catalent: Catalent is a major cell therapy CDMO providing process development and GMP manufacturing services, overlapping with MaxCyte's enabling-tools positioning as a partner to cell therapy developers seeking manufacturing solutions.
  • Sartorius AG: Sartorius provides bioprocessing equipment and cell therapy manufacturing solutions that compete in adjacent steps of the cell therapy workflow, serving many of the same biopharma customers with broader portfolios that include cell engineering alternatives.
  • Cytiva (Danaher): Cytiva offers a broad portfolio of bioprocessing and cell therapy manufacturing equipment under Danaher, competing with MaxCyte at the manufacturing scale-up stage and serving overlapping cell therapy developer customers globally.

Others

  • Agilent Technologies: Agilent provides life sciences instrumentation and analytical tools serving similar biopharma and academic research customers as MaxCyte, and recently hired MaxCyte's incoming CFO from its investor relations function, signaling overlap in talent markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

MaxCyte social profiles

Digital presence

MaxCyte compliance and trust

Trust signal

Compliance3 records

MaxCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MaxCyte leadership team

Management profile

Number of profiles

Profiles6 records

MaxCyte subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MaxCyte funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MaxCyte M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MaxCyte

What does MaxCyte do?

MaxCyte develops and commercializes non-viral Flow Electroporation technology for cell engineering, offering a portfolio of five ExPERT instruments (DTx, ATx, STx, GTx, VLx) that scale from discovery through GMP manufacturing. The company sells proprietary processing assemblies, buffers, and reagents as consumables, and provides gene editing risk assessment services through its SeQure sub-brand. Customers include biotech firms, biopharmaceutical companies, and academic institutions developing cell therapies, gene therapies, vaccines, and biologics.

Is MaxCyte a public or private company?

MaxCyte is a public company. It is classified as public and is currently operating.

When was MaxCyte founded?

MaxCyte was founded in 1999. It employs 101 to 250 people.

Where is MaxCyte based?

MaxCyte is headquartered in Rockville, United States, in the North America region.

How does MaxCyte make money?

Three revenue lines are on record. Electroporation Instruments and Consumables are the primary driver. The others are strategic Platform Licensing (SPL) and seQure Gene Editing Services.

Who are MaxCyte's main competitors?

Direct peers on record are Thermo Fisher Scientific, Bio-Rad Laboratories, Harvard Bioscience (BTX) and BEX Co., Ltd.. Miltenyi Biotec is listed as an emerging player. Broad incumbents are Lonza Group, Catalent, Sartorius AG and Cytiva (Danaher). Agilent Technologies is listed as an others.

Does MaxCyte have an API?

No public API is recorded for MaxCyte.

What industry is MaxCyte in?

MaxCyte's product category is Cell Engineering Instrumentation and Services. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAM, Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comMaxCyte at Stephens conference: akron deal broadens cell therapy reachMaxCyte announced its acquisition of Akron Biotech at the Stephens conference, expanding its cell therapy reach to the full workflow. The deal nearly doubles annual revenue, and the company raised full-year 2026 revenue guidance to $34.5 million. Management expects cash flow positivity by late 2027 or early 2028.Pulse 2.0MaxCyte: $151.8 Million Akron Bio Acquisition Expands Cell Therapy PlatformMaxCyte agreed to acquire Akron BioProducts for $151.8 million, with the deal expected to close before end of 2026. The acquisition is projected to nearly double MaxCyte's revenue base and reduce annual cash burn to under $10 million in 2027. Consideration includes $105 million cash, shares, and deferred payments.Seeking AlphaMaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability (NASDAQ:MXCT)MaxCyte entered a definitive agreement to acquire Akron Bio from Arcline Investment Management. Akron's revenue is expected to be $28 million for 2026, contributing to MaxCyte's projected at least $34.5 million in 2026 revenue.The Motley FoolMaxCyte (MXCT) Q3 2026 Earnings Call TranscriptMaxCyte reported Q3 2026 revenue of $10.2 million, up 49% year-over-year, and announced a $151.8 million acquisition of Akron Bio. The company raised its full-year revenue guidance to at least $34.5 million and expects combined revenue over $60 million in 2026.The Motley FoolMaxCyte (MXCT) Q3 2026 Earnings Call TranscriptMaxCyte reported Q3 2026 revenue of $10.2 million, up 49% year-over-year, and announced a $151.8 million acquisition of Akron Bio. The company raised its standalone full-year revenue guidance to at least $34.5 million and expects combined revenue over $60 million in 2026.Dealroom.coMaxCyte secures $75M credit facility to fund Akron Bio acquisitionMaxCyte secured a $75M credit facility from MidCap Financial to fund its $151.8M acquisition of Akron BioProducts. The deal includes $105M cash, $26.8M in shares, and two $10M deferred payments. MaxCyte expects Akron's revenue to cut combined cash burn to under $10M in 2027.MarketScreenerMaxCyte, Inc. Secures A New Credit Facility with MidCap Financial of Up to $75.0 MillionMaxCyte secured a $75 million credit facility from MidCap Financial, including a $55 million term loan and $20 million revolving credit. It expects to draw $20 million under the term loan and $2 million under the revolving credit at closing. The company plans to use these funds, along with cash and remaining availability, to fund operations through profitability.ChartmillMaxCyte (NASDAQ:MXCT) Tops Q3 Estimates, Raises 2026 Revenue Outlook Ahead of Akron Bio AcquisitionMaxCyte reported Q3 2026 revenue of $10.152 million, beating estimates by 33%, and raised full-year 2026 guidance to at least $34.5 million. The company also announced a proposed $105 million acquisition of Akron Bio, which would nearly double its revenue base.American Banking and Market NewsMaxCyte (MXCT) Expected to Release Quarterly Earnings on TuesdayMaxCyte is expected to release Q3 2026 earnings on Tuesday, November 10th, after market close. Analysts forecast EPS of ($0.08) and revenue of $7.39 million, with a consensus "Hold" rating and average target price of $5.00.